CAS 151213-40-0
:(4aS,7aS)-Octahydro-1H-pyrrolo[3,4-b]pyridine
Formule :C7H14N2
InChI :InChI=1S/C7H14N2/c1-2-6-4-8-5-7(6)9-3-1/h6-9H,1-5H2/t6-,7+/m0/s1
Code InChI :InChIKey=KSCPLKVBWDOSAI-NKWVEPMBSA-N
SMILES :[C@]12([C@@](CNC1)(NCCC2)[H])[H]
Synonymes :- (1S,6S)-2,8-Diazabicyclo[4.3.0]nonane
- (1S,6S)-cis-2,8-Diazabicyclo[4.3.0]nonane
- (4AS,7aS)-Octahydro-1H-pyrrole[3,4-b]pyridine
- (4aS,7aS)-2,3,4,4a,5,6,7,7a-octahydro-1H-pyrrolo[3,4-b]pyridine dihydrochloride
- (4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridine
- (S,S)-2,8-Diazabicyclo[4,3,0]Nonane
- (S,S)-2,8-Diazabicyclo[4,3,0]Onoane
- (S,S)-2,8-Diazabicylco(4,3,0)Nonane
- 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)-
- 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS-cis)-
- Cis-Octahydropyrrolo[3,4-B]Pyridine
- Moxifloxacin side chain
- Voir plus de synonymes
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
10 produits trouvés.
(1S,6S)-2,8-Diazabicyclo[4.3.0]nonane
CAS :Formule :C7H14N2Degré de pureté :>98.0%(GC)Couleur et forme :Colorless to Light orange to Yellow clear liquidMasse moléculaire :126.20(S,S)-2,8-Diazabicyclo [4,3,0]nonane
CAS :Formule :C7H14N2Degré de pureté :97%Couleur et forme :LiquidMasse moléculaire :126.1995(1S,6S)-2,8-Diazabicyclo[4.3.0]Nonane
CAS :(1S,6S)-2,8-Diazabicyclo[4.3.0]NonaneFormule :C7H14N2Degré de pureté :98%Masse moléculaire :126.2(S,S)-2,8-Diazabicyclo[4.3.0]nonane
CAS :(4aS,7aS)-Octahydro-1H-pyrrolo[3,4-b]pyridineFormule :C7H14N2Degré de pureté :97%Masse moléculaire :126.21H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)-
CAS :Degré de pureté :97%Couleur et forme :LiquidMasse moléculaire :126.2(S,S)-2,8-Diazabicyclo[4.3.0]nonane
CAS :Produit contrôléApplications Moxifloxacin intermediate
Formule :C7H14N2Couleur et forme :NeatMasse moléculaire :126.2(1S,6S)-2,8-Diazabicyclo[4.3.0]nonane
CAS :(1S,6S)-2,8-Diazabicyclo[4.3.0]nonane is a chiral compound that can be made from the reaction of an organic acid with an amino alcohol. The enantiomers of this compound have shown to be effective against methicillin-resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis. The synthetic process for this compound was originally developed in the 1980s by researchers at the University of Illinois. They were able to show that it was possible to make a carbonyl reduction product using imidodicarbonic acid and an organic solvent. This led to the synthesis of moxifloxacin hydrochloride, which is used as a treatment for bacterial infections such as tuberculosis or pneumonia.Formule :C7H14N2Degré de pureté :Min. 95%Couleur et forme :Colourless To Brown LiquidMasse moléculaire :126.2 g/mol









